Controlling trisulfide modification in recombinant monoclonal antibody produced in fed-batch cell culture

Biotechnology and Bioengineering

Volumn 109, Issue 10, 2012, Pages 2523-2532

  Kshirsagar, Rashmi ^a   Mcelearney, Kyle ^a   Gilbert, Alan ^a   Sinacore, Marty ^a   Ryll, Thomas ^a  

^a BIOGEN   (United States)

Author keywords

CHO cells; Cysteine; Disulfide; Post translation modification; Recombinant antibodies; Trisulfides

Indexed keywords

CHO CELL; CYSTEINE; DISULFIDE; POST-TRANSLATION MODIFICATION; RECOMBINANT ANTIBODY; TRISULFIDES;

AMINO ACIDS; BATCH CELL CULTURE; BIOREACTORS; COVALENT BONDS; HYDROGEN SULFIDE; MONOCLONAL ANTIBODIES; SULFUR;

TRANSLATION (LANGUAGES);

CYSTEINE; DISULFIDE; HYDROGEN SULFIDE; IMMUNOGLOBULIN G1 ANTIBODY; RECOMBINANT ANTIBODY; SULFIDE; SULFUR; TRISULFIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOREACTOR; CELL CULTURE; DISULFIDE BOND; FED BATCH CULTURE; FEEDING; HEAVY CHAIN; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN PROCESSING;

ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CULTURE MEDIA; CYSTEINE; IMMUNOGLOBULIN G; RECOMBINANT PROTEINS; SULFIDES;

EID: 84865394272     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.24511     Document Type: Article

References (48)

1. Ahrer K, Jungbauer A. 2006. Chromatographic and electrophoretic characterization of protein variants. J Chromatogr B Analyt Technol Biomed Life Sci 841(1-2): 110-122.
2. Andersson C, Edlund PO, Gellerfors P, Hansson Y, Holmberg E, Hult C, Johansson S, Kordel J, Lundin R, MendelHartvig I, Noren B, Wehler T, Widmalm G, Ohman J. 1996. Isolation and characterization of a trisulfide variant of recombinant human growth hormone formed during expression in Escherichia coli. Int J Pept Protein Res 47(4): 311-321.
3. Aono H, Wen D, Zang L, Houde D, Pepinsky RB, Evans DRH. 2010. Efficient on-column conversion of lgG(1) trisulfide linkages to native disulfides in tandem with Protein A affinity chromatography. J Chromatogr A 1217(32): 5225-5232.
4. Banks DD, Gadgil HS, Pipes GD, Bondarenko PV, Hobbs V, Scavezze JL, Kim J, Jiang XR, Mukku V, Dillon TM. 2008. Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity, stability, and biological activity. J Pharm Sci 97(2): 775-790.
5. Barnes CAS, Lim A. 2007. Applications of mass spectrometry for the structural characterization of recombinant protein pharmaceuticals. Mass Spectrom Rev 26(3): 370-388.
6. Becker P, Christensen T. Novo Nordisk A/S, assignee. 2006. Method for preventing formation of trisulfide derivatives of polypeptides. Patent WO 2006/069940.
7. Birch JR, Racher AJ. 2006. Antibody production. Adv Drug Deliv Rev 58(5-6): 671-685.
8. Breton J, Avanzi N, Valsasina B, Sgarella L, Lafiura A, Breme U, Orsini G, Wenisch E, Righetti PG. 1995. Detection of traces of a trisulfide derivative in the preparation of a recombinant truncated interleukin-6 mutein. J Chromatogr A 709(1): 135-146.
9. CanovaDavis E, Baldonado IP, Chloupek RC, Ling VT, Gehant R, Olson K, GilleceCastro BL. 1996. Confirmation by mass spectrometry of a trisulfide variant in methionyl human growth hormone biosynthesized in Escherichia coli. Analyt Chem 68(22): 4044-4051.
10. Chadd HE, Chamow SM. 2001. Therapeutic antibody expression technology. Curr Opin Biotechnol 12(2): 188-194.
11. Chen XL, Jhee KH, Kruger WD. 2004. Production of the neuromodulator H2S by cystathionine beta-synthase via the condensation of cysteine and homocysteine. J Biol Chem 279(50): 52082-52086.
12. Chiang GG, Sisk WP. 2005. Bcl-x(L) mediates increased production of humanized monoclonal antibodies in Chinese hamster ovary cells. Biotechnol Bioeng 91(7): 779-792.
13. De Jesus M, Wurm FM. 2011. Manufacturing recombinant proteins in kg-ton quantities using animal cells in bioreactors. Eur J Pharm Biopharm 78(2): 184-188.
14. Flatman S, Alam I, Gerard J, Mussa N. 2007. Process analytics for purification of monoclonal antibodies. J Chromatogr B Analyt Technol Biomed Life Sci 848(1): 79-87.
15. Furne J, Saeed A, Levitt MD. 2008. Whole tissue hydrogen sulfide concentrations are orders of magnitude lower than presently accepted values. Am J Physiol Regul Integr Comp Physiol 295(5): R1479-R1485.
16. Gallogly MM, Mieyal JJ. 2007. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr Opin Pharmacol 7(4): 381-391.
17. Glockshuber R, Schmidt T, Plueckthun A. 1992. The disulfide bonds in antibody variable domains effects of stability folding in-vitro and functional expression in Escherichia coli. Biochemistry 31(5): 1270-1279.
18. Gu S, Wen D, Weinreb PH, Sun Y, Zhang L, Foley SF, Kshirsagar R, Evans D, Mi S, Meier W, Pepinsky RB. 2010. Characterization of trisulfide modification in antibodies. Analyt Biochem 400(1): 89-98.
19. Harman LS, Mottley C, Mason RP. 1984. Free radical metabolites of L-cysteine oxidation. J Biol Chem 259(9): 5606-5611.
20. Henderson JW, Ricker RD, Bidlingmeyer BA, Woodward C. 2006. Rapid, accurate, sensitive and reproducible analysis of amino acids. Palo Alto, CA: Agilent Technologies 5980-1193EN.
21. Huang Y, Hu W, Rustandi E, Chang K, Yusuf-Makagiansar H, Ryll T. 2010. Maximizing productivity of CHO cell-based fed-batch culture using chemically defined media conditions and typical manufacturing equipment. Biotechnol Progr 26(5): 1400-1410.
22. Jespersen AM, Christensen T, Klausen NK, Nielsen PF, Holmegaard-Sorensen H. 1994. Characterisation of a trisulphide derivative of biosynthetic human growth hormone produced in Escherichia coli. Eur J Biochem 219(1-2): 365-373.
23. Khetan A, Huang Y, Dolnikova J, Pederson NE, Wen D, Yusuf-Makagiansar H, Chen P, Ryll T. 2010. Control of misincorporation of serine for asparagine during antibody production using CHO cells. Biotechnol Bioeng 107(1): 116-123.
24. Li F, Vijayasankaran N, Shen A, Kiss R, Amanullah A. 2010. Cell culture processes for monoclonal antibody production. Mabs 2(5): 466-479.
25. Liu HC, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. 2008. Heterogeneity of monoclonal antibodies. J Pharm Sci 97(7): 2426-2447.
26. Liu HC, Chumsae C, Gaza-Bulseco G, Hurkmans K, Radziejewski CH. 2010. Ranking the susceptibility of disulfide bonds in human IgGs1 antibodies by reduction, differential alkylation, and LC-MS analysis. Analyt Chem 82(12): 5219-5226.
27. Markakis P, Tappel AL. 1960. Products of γ-irradiation of cysteine and cystine1. J Am Chem Soc 82(7): 1613-1617.
28. Nath KA, Salahudeen AK. 1993. Autoxidation of cysteine generates hydrogen peroxide: Cytotoxicity and attenuation by pyruvate. Am J Physiol Renal Physiol 264(2): F306-F314.
29. Nielsen RW, Tachibana C, Hansen NE, Winther JR. 2011. Trisulfides in proteins. Antioxid Redox Signal 15(1): 67-75.
30. Okado-Matsumoto A, Guan ZQ, Fridovich I. 2006. Modification of Cysteine 111 in human Cu, Zn-superoxide dismutase. Free Radic Biol Med 41(12): 1837-1846.
31. Pavlou AK, Reichert JM. 2004. Recombinant protein therapeutics-Success rates, market trends and values to 2010. Nat Biotechnol 22(12): 1513-1519.
32. Prentice HL, Tonkin CJD, Caamano L, Sisk WP. 2007. High level expression of proteins using sequences from the ferritin heavy chain gene locus. J Biotechnol 128(1): 50-60.
33. Pristatsky P, Cohen SL, Krantz D, Acevedo J, Ionescu R, Vlasak J. 2009. Evidence for trisulfide bonds in a recombinant variant of a human IgG2 monoclonal antibody. Analyt Chem 81(15): 6148-6155.
34. Reichert JM. 2008. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 9(6): 423-430.
35. Reichert JM. 2010. Metrics for antibody therapeutics development. Mabs 2(6): 695-700.
36. Reichert JM. 2011. Antibody-based therapeutics to watch in 2011. Mabs 3(1): 76-99.
37. Reichert JM, Rosensweig CJ, Faden LB, Dewitz MC. 2005. Monoclonal antibody successes in the clinic. Nat Biotechnol 23(9): 1073-1078.
38. Rustandi RR, Washabaugh MW, Wang Y. 2008. Applications of CE SDS gel in development of biopharmaceutical antibody-based products. Electrophoresis 29(17): 3612-3620.
39. Shukla AA, Thoemmes J. 2010. Recent advances in large-scale production of monoclonal antibodies and related proteins. Trends Biotechnol 28(5): 253-261.
40. Smelko JP, Wiltberger KR, Hickman EF, Morris BJ, Blackburn TJ, Ryll T. 2011. Performance of high intensity fed-batch mammalian cell cultures in disposable bioreactor systems. Biotechnol Progr 27(5): 1358-1364.
41. Stipanuk MH, Beck PW. 1982. Characterization of the enzymic capacity for cysteine desulfhydration in liver and kidney of the rat. Biochem J 206(2): 267-278.
42. Vlasak J, Ionescu R. 2008. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Curr Pharm Biotechnol 9(6): 468-481.
43. Walsh G. 2010. Biopharmaceutical benchmarks 2010. Nat Biotechnol 28(9): 917-924.
44. Wang Y, Lu QZ, Wu SL, Karger BL, Hancock WS. 2011. Characterization and Comparison of disulfide linkages and scrambling patterns in therapeutic monoclonal antibodies: Using LC-MS with electron transfer dissociation. Analyt Chem 83(8): 3133-3140.
45. Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22(11): 1393-1398.
46. Yoon S, Kim Y-S, Shim H, Chung J. 2010. Current perspectives on therapeutic antibodies. Biotechnol Bioprocess Eng 15(5): 709-715.
47. Yu M, Hu ZL, Pacis E, Vijayasankaran N, Shen A, Li F. 2011. Understanding the intracellular effect of enhanced nutrient feeding toward high titer antibody production process. Biotechnol Bioeng 108(5): 1078-1088.
48. Zhang ZQ, Pan H, Chen XY. 2009. Mass spectrometry for structural characterization of therapeutic antibodies. Mass Spectrom Rev 28(1): 147-176.